Cognitive impairment

Tau proteins aggregate to neurofibrillary tangles in a neuron axon

Study reveals new therapeutic target in neurodegenerative disease

12 October 2022

Early-cognitive decline may result from a shift in the ratio of a protein sub-type in our brain cells triggering cell-loss, according to a new study. The discovery, published in Scientific Reports, provides a new therapeutic target to prevent the onset of neurodegenerative diseases including dementia and Alzheimer’s. It is the first study to examine the […]

Jigsaw puzzle of the brain

New Alzheimer’s treatment reduces decline in Phase III trial

6 October 2022

A new Alzheimer’s disease (AD) treatment has been shown to reduce clinical decline in mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology in the brain.  Eisai and Biogen’s anti-amyloid beta (Aβ) protofibril antibody lecanemab met the primary endpoint and all key secondary endpoints in the global Phase […]

CT scans of the brain

Potential Alzheimer’s drug receives US patent

12 September 2022

The United States Patent Office (USPTO) has issued a patent covering drug candidate ACD856, which is currently being developed to treat Alzheimer’s disease and other disorders with cognitive impairment. ACD856 is part of AlzeCure Pharma’s NeuroRestore platform, which it is hoped could provide treatments for Alzheimer’s, Parkinson’s disease and depression. These drugs stimulate several important […]